Table 1.
Baseline patient, disease, and HCT characteristics.
| Study ID | Age (years) | Sex | Race/ethnicity | HCT indication | Time from HCT (years) | Donor | HSC source | Prep regimen | GVHD ppx |
|---|---|---|---|---|---|---|---|---|---|
| EPIC2014-01 | 35 | M | White | ALL | 0.5 | MUD | BM | Flu/Mel | Tac/MTX |
| EPIC2014-05 | 59 | M | Native Hawaiian or Other Pacific Islander | AML | 0.3 | MRD | PBSC | Flu/Mel | Tac/MTX |
| EPIC2014-06 | 26 | M | White | HL | 0.7 | MRD | PBSC | Flu/Bu | Tac/MMF |
| EPIC2014-07 | 53 | M | White | AML | 3.4 | URD | PBSC | Bu/Cy | Tac/NR |
| EPIC2014-12 | 50 | M | Black or African American | CTCL | 2.6 | MUD | PBSC | Flu/Mel | Tac/MTX |
| EPIC2014-13 | 34 | M | White | MF | 4.5 | MMUD | PBSC | Bu/Cy | Tac/MTX |
| EPIC2014-14 | 55 | M | Black or African American | MDS | 3.1 | MRD | BM | Bu/Cy | Tac/MTX |
| EPIC2014-15 | 26 | M | White, Hispanic, or Latino | CML | 0.4 | MUD | PBSC | Bu/Cy | Tac/MTX |
| EPIC2014-16 | 28 | F | White | HL | 6.5 | URD | PBSC | FluMel | Tac/MTX |
| EPIC2014-17 | 75 | F | White | MDS | 4.7 | MUD | PBSC | FluTBI | Tac/MMF |
| EPIC2014-18 | 37 | F | Black or African American | CML | 0.6 | MRD | PBSC | FluMel | Tac/MTX |
HCT, hematopoietic cell transplantation; HSC, hematopoietic stem cell; Prep, preparative; GVHD, graft-versus-host disease; ppx, prophylaxis; M, male; F, female; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HL, Hodgkin lymphoma; CTCL, cutaneous T-cell lymphoma; MF, myelofibrosis; MDS, myelodysplastic syndrome; MUD, matched unrelated donor; MRD, matched related donor; URD, unrelated donor; MMUD, mismatched unrelated donor; BM, bone marrow; PBSC, peripheral blood stem cells; Flu, fludarabine; Mel, melphalan; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; Tac, tacrolimus; MTX, methotrexate; MMF, mycophenolate mofetil; NR, not reported.